Health Care Technology
Company Overview of Merge eClinical Inc.
Merge eClinical Inc. offers software and services to pharmaceutical, biotechnology, medical device, and contract research organizations. It offers etrials Synchronized Intelligence, an adaptive and integrated framework across the clinical trial process; and etrials Trial Intelligence that is used for managing and analyzing the progress of clinical trials via Web-based tools for collecting, managing, and analyzing real-time clinical trial information. The company also provides etrials Site Intelligence, a trial monitoring and control tool that provides access to clinical site performance, logistics, and protocol compliance; and detrials Patient Intelligence that offers modalities for capturin...
4000 Aerial Center Parkway
Morrisville, NC 27560
Founded in 1999
Key Executives for Merge eClinical Inc.
Chief Executive Officer of Europe and President of Europe
Chief Information Officer and Vice President of Information Technology
Director of Business Development and Director of eClinical Solutions
Compensation as of Fiscal Year 2015.
Merge eClinical Inc. Key Developments
Merge eClinical Launches New Study Connect Mobile App
Jun 17 15
Merge eClinical has launched Study Connect, a new mobile app which allows eClinicalOS, or eCOS, users to perform clinical trial management functions from their iOS-based mobile devices. Seamlessly integrated with eCOS, Study Connect enables researchers to: manage randomization of subjects; coordinate dispensing and inventory management; unblind individual subjects, as circumstances warrant; stay connected with real-time customized notifications; monitor enrollment and establish milestone alerts; share top-level statistics for each study with key stakeholders using the study dashboard; expedite approval response times for critical study decisions such as patient study eligibility; and maintain security with the ability to set customized role-based permissions for individual studies. Managing study decisions and being notified of adverse events alone would make for a useful mobile EDC, but Study Connect gives eCOS users so much more. It really serves as a natural extension of their desktops and laptops.
PPCE Selects eClinicalOS Data Management Platform from Merge eClinical for Rheumatoid Arthritis Study
Nov 19 14
PPCE selected the eClinicalOS data management platform from Merge eClinical for a rheumatoid arthritis study for the pharmaceuticals company. While the number of eClinicalOS-based trials outside the U.S. has grown steadily since its launch in 2012, this study represents the first time the platform has been used to administer a trial in India. The eClinicalOS platform's design allowed the PPCE team to build and launch the study in only seven weeks. PPCE and its client were specific in the functions and features needed from a data management system. PPCE said that more stringent regulations coupled with increased cost pressure are pushing the clinical research market to adopt technology to an even greater extent than in recent years.
Verthermia Selects eClinicalOS Data Management Platform from Merge eClinical for Whole Body Hyperthermia Ovarian Cancer Treatment Trial
Nov 6 14
Verthermia Inc. has selected the Merge eClinicalOS data management platform from Merge eClinical for its clinical trial exploring the potential of whole body hyperthermia as a standalone treatment for women with Stage III or IV ovarian cancer. The U.S. Food and Drug Administration (FDA) approved the company's application to conduct the study, which began in January. The trial is the company's first cancer therapy the FDA has approved for clinical trial and it is in the safety phase of studying the treatment of late-stage solid-tumor cancers. Verthermia is actively recruiting patients as the initial study is expected to last approximately two years. The study is designed to raise a patient's core temperature to therapeutic range via the CoreHFC(TM) medical device, maintaining that temperature, detoxifying the blood and returning the patient to normal body temperature. As proven by past studies, a key advantage of regional and whole body hyperthermia is that it helps other forms of cancer treatment work better because heating cancer cells to temperatures above normal makes them easier to destroy using radiation and certain chemotherapy drugs.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries